July 19th 2024
"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Partial nephrectomy shows increased survival benefit
April 15th 2013A recently published population-based study reinforces prior evidence from retrospective studies of the increased survival benefit of partial nephrectomy over radical nephrectomy, and suggests a cancer-specific survival benefit for nephron-sparing approaches as well.
Metastatic renal cell carcinoma agent nearly doubles survival
April 15th 2013A personalized immunotherapy (AGS-003) nearly doubled expected progression-free survival and overall survival when added to standard sunitinib (Sutent) in patients with unfavorable-risk metastatic renal cell carcinoma, according to results from a single-arm phase II study.
Novel VEGF inhibitor may play role in advanced renal cell carcinoma
March 6th 2013Use of tivozanib, an experimental tyrosine kinase inhibitor (TKI) with increased specificity and potency for the vascular endothelial growth factor (VEGF) receptor, as initial targeted therapy for patients with advanced renal cell carcinoma did not translate into improved overall survival compared with sorafenib (Nexavar) in a phase III clinical trial.
Study: Surveillance is safe for small renal masses
February 19th 2013A large retrospective study of older patients diagnosed with small kidney tumors showed that patients who undergo surgery to remove these tumors have the same risk of dying of kidney cancer over a 5-year period as those who undergo surveillance.